Identification of the ligand binding site in Fas (CD95) and analysis of Fas-ligand interactions

Proteins: Structure, Function and Genetics

Volumn 35, Issue 4, 1999, Pages 475-482

  Bajorath, Jürgen ^a,b  

^a MDS Inc   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Binding site; Cell surface proteins; Comparative molecular modeling; Critical residues; Mutagenesis; Receptor ligand interactions; Superfamilies

Indexed keywords

CELL SURFACE PROTEIN; FAS ANTIGEN;

APOPTOSIS; ARTICLE; BINDING SITE; LIGAND BINDING; MOLECULAR INTERACTION; PRIORITY JOURNAL; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

EID: 0033151892     PISSN: 08873585     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0134(19990601)35:4<475::AID-PROT11>3.0.CO;2-0     Document Type: Article

References (31)

1. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S-I, Sameshima M, Hase A, Seto Y, Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-243.
2. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1994;75:1169-1178.
3. Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-1456.
4. Peter ME, Krammer PH. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol 1998;10:545-551.
5. Bajorath J. Three-dimensional models of immune cell surface proteins and identification of binding sites. J Mol Model 1998;4:1-11.
6. Bajorath J. Cell surface receptors and adhesion molecules, three-dimensional structures. In: Delves PJ, Roitt EM, editors. Encyclopedia of immunology, 2nd edition. London: Academic Press; 1998, p 515-520.
7. Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science 1994;264:667-668.
8. Naismith JH, Sprang SR. Modularity of the TNF-receptor family. Trends Biochem Sci 1998;23:74-79.
9. Jones EY, Stuart DI, Walker NPC. Structure of tumor necrosis factor. Nature 1989;338:225-228.
10. Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld H-J, Broger C, Loetscher H, Lesslauer W. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation. Cell 1993;73:431-445.
11. Greer J. Comparative modelling methods: application to the family of mammalian serine proteases. Proteins 1990;7:317-334.
12. Mosimann S, Meleshko R, James MNG. A critical assessment of comparative molecular modeling of tertiary structures of proteins. Proteins 1995;23:301-317.
13. Martin ACR, MacArthur MW, Thornton JM. Assessment of comparative modeling in CASP2. Proteins 1997;Suppl. 1:14-28.
14. Sali A. Modelling mutations and homologous proteins. Curr Opin Biotechnol 1995;6:437-451.
15. Hollenbaugh D, Grosmaire LS, Kullas CD, et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J 1992;11:4313-4321.
16. Bajorath J. Detailed comparison of two molecular models of the human CD40 ligand with an X-ray structure and critical assessment of model-based mutagenesis and residue mapping studies. J Biol Chem 1998;273:24603-24609.
17. Karpusas M, Hsu Y-M, Wang J-H et al. 2 A crystal structure of an extracellular fragment of human CD40 ligand. Structure 1995;3: 1031-1039.
18. Bajorath J, Aruffo A. Prediction of the three-dimensional structure of the human Fas receptor by comparative molecular modeling. J Comput Aided Mol Des 1997;11:3-8.
19. Peitsch MC, Tschopp J. Comparative molecular modeling of the Fas ligand and other members of the TNF family. Mol Immunol 1995;32:761-772.
20. Naismith JH, Devine TQ, Brandhuber BJ, Sprang SR. Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor. J Biol Chem 1995;270:13303-13307.
21. Bajorath J, Stenkamp R, Aruffo A. Knowledge-based protein modeling: Concepts and examples. Protein Sci 1993;2:317-334.
22. Bajorath J, Marken JS, Chalupny NJ et al. Analysis of gp39/CD40 interactions using molecular models and site directed mutagenesis. Biochemistry 1995;34:9884-9892.
23. Starling GC, Bajorath J, Emswiler J, Ledbetter JA, Aruffo A, Kiener PA. Identification of amino acid residues important for ligand binding to Fas. J Exp Med 1997;185:1487-1492.
24. Schneider P, Bodmer J-L, Holler N et al. Characterization of Fas (Apo-1, CD95)-Fas ligand interactions. J Biol Chem 1998;272: 18827-18832.
25. Peitsch MC. ProMod and Swiss-Model: Internet-based tools for automated comparative protein modelling. Biochem Soc Trans 1996;24:274-279.
26. Fadeel B, Lindberg J, Achour A, Chiodi F. A three-dimensional model of the Fas/APO-1 molecule: cross-reactivity of anti-Fas antibodies explained by structural mimicry of antigenic sites. Int Immunol 1998;10:131-140.
27. Singh J, Garber E, Van Vlijmen H, Karpusas M, Hsu Y-M, Zheng Z, Naismith JH, Thomas D. The role of polar interactions in the molecular recognition of CD40L with its receptor CD40. Protein Sci 1998;7:1124-1135.
28. Starling GC, Kiener PA, Aruffo A, Bajorath J. Analysis of the ligand binding site in Fas by site-directed mutagenesis and comparison with TNFR and CD40. Biochemistry 1998;37:3723-3726.
29. Bajorath J. Analysis of Fas-ligand interactions using a molecular model of the receptor-ligand interface. J Comput Aided Mol Des 1998: in press.
30. Bernstein FC, Koetzle TF, Williams GJB et al. The protein data bank: a computer based archival file for macromolecular structures. J Mol Biol 1977;112:535-542.
31. Feng DF, Doolittle RF. Progressive alignment and phylogenetic tree construction of protein sequences. Meth Enzymol 1990;183: 375-387.